MEDICAL ONCOLOGY DEVELOPMENT RESEARCH

项目0019的中心焦点是将临床观察联系起来 与实验室结果一起产生关于肿瘤的假说 进展或对治疗的反应，并在 诊所。临床观察结果将来自于重点研究 选择恶性血液病和乳腺癌。肿瘤的类型 进展和治疗失败将用于指导实验室 产生克服毒品的新方法的核心和项目 使用新药、化学增敏剂或药物变化产生耐药性 计划或给药。 该项目的具体目标是： 1.将临床观察作为实验室的假设 对实验室说明进行调查和改进； 2.为选定的血液病开发新的治疗方法 使用实验室开发的铅的恶性肿瘤和乳腺癌； 3.研究癌症的生物学和科学基础的新疗法 通过将临床观察和治疗结果与 药物开发的体内和体外药物动力学模型，以及 耐药情况调查； 4.检验实验室项目研究人员提出的假设。

The central focus of Project 0019 is to correlate clinical observations with laboratory results to generate hypotheses regarding tumor progression or response to therapy, and to test these new hypotheses in the clinic. Clinical observations will result from studies focused on select hematologic malignancies and breast cancer. Patterns of tumor progression and treatment failure will serve to guide the laboratory cores and projects to produce new approaches to overcoming drug resistance using novel drugs, chemosensitizers, or changes in drug schedule or dosing. The specific aims of project are: 1. To present clinical observations as hypotheses for laboratory investigations and refinements of laboratory directions; 2. To develop new therapeutic approaches for select hematologic malignancies and breast cancer using leads developed in the laboratory; 3. To study the biology and scientifically based new therapy of cancers by interrelating clinical observations and treatment outcome with pharmacokinetics, in vivo and in vitro models for drug development, and the investigation of drug resistance; 4. To test hypotheses generated by investigators of laboratory projects.